Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





A Phase 2a, Open-Label Pilot Study to Evaluate

Cardiology
Amin Sabet
A Phase 2a, Open-Label Pilot Study to Evaluate the Safety Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis
Cardiac Disease
Heart - Cardiovascular Circulatory

Study Description

Eligibility

  1. Participants are male or female greater than or equal to 18 years up to less than or equal to 75 years of age.
  2. Capable of giving signed informed consent and able to comply with the protocol
  3. Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event
  4. Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.
  5. CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP less than or equal to 1 mg/dL must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)
  6. Pericarditis pain score greater than or equal to 4 based on the 11-point NRS.
  7. Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving these treatments)
  1. Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.
  2. History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.
  3. Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.